Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

NCT07302841 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer Non-resectable

Interventions

DRUG: Experimental: Tunlametinib+gemcitabine+albumin paclitaxel + cetuximab β

Sponsor

Tianjin Medical University Cancer Institute and Hospital